The development of a world-first intravenous (IV) Passport has caught the world’s attention with 20 countries downloading the application and an award from the consumer-led Australian Patients Association.
A drug normally used to prevent tissue rejection following organ transplants could be repurposed to help treat human metapneumovirus (HMPV) infection in children.
Griffith University researchers are conducting a world-leading trial assessing the role of exercise as therapy for women with recurrent ovarian cancer
An impressive final year Griffith student, who overcame a cancer diagnosis at 15 before embarking on a medical degree, has been awarded a prestigious 2022 Australia-At-Large Rhodes Scholarship.
After the Pandemic: Imagining the Future Our response to coronavirus will shape Australia for decades to come. It has been...
Two of 2020’s top high school graduates, one of whom has already completed an exciting cancer research project at Griffith, are now on a fast-track to exciting careers in medicine.
Griffith University researchers have discovered a novel approach that could lead to the personalised design of anticancer drugs that resist...
A $2million grant from Cancer Council of Queensland will help Griffith researchers continue vital work in bolstering survival rates in women treated for ovarian cancer.
A new anti-cancer drug for prostate cancer overcomes the twin problems plaguing researchers for decades. It halts metastasis (tumour spread) and drug resistance.
Alpha blockers may reduce the risk of prostate cancer recurrence a Griffith University study has found.
